Xilio Therapeutics, Inc. (XLO)
About Xilio Therapeutics, Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $43.8M
- Net income
- -$35.0M
- Total assets
- $154.7M
- Market cap
- $50.6M
- Operating margin
- -95.9%
- Net margin
- -80.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $43.8M
- Operating expenses
- $85.7M
- Operating income
- -$42.0M
- Income tax
- $0
- Net income
- -$35.0M
- EPS (basic)
- $-4.19
- EPS (diluted)
- $-4.19
Balance sheet
- Total assets
- $154.7M
- Current assets
- $145.0M
- Total liabilities
- $119.4M
- Current liabilities
- $56.3M
- Shareholders’ equity
- $35.3M
Cash flow
- Operating cash flow
- -$5.0M
- Investing cash flow
- -$518.0K
- Financing cash flow
- $87.8M
- Net cash flow
- $82.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $50.6M
- EPS (diluted)
- $-4.19
- Shares outstanding
- 5.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 22, 2021
Xilio Therapeutics, Inc. (XLO) Stock Price
- Reported a net loss of $35.0M in FY2025.
- Trading 28% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Xilio Therapeutics, Inc..
Write a review
News about Xilio Therapeutics, Inc.
News & sentiment via Polygon.io
Xilio Therapeutics, Inc.: frequently asked questions
Is Xilio Therapeutics, Inc. an American company?
Xilio Therapeutics, Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States.
Is Xilio Therapeutics, Inc. publicly traded?
Yes — Xilio Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol XLO on the NASDAQ.
What does Xilio Therapeutics, Inc. do?
Xilio Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
